About Our Organization
The Run4Life event benefits cancer research, including the Caine Halter Lung Cancer Research Fund, and patient support through the Cancer Institute of Greenville Health System and the Cancer Society of Greenville County. Proceeds from the 10th anniversary race will fund GHS Institute for Translational Oncology (ITOR) projects, specific lung cancer initiatives, as well as patient support programs offered through the Cancer Society of Greenville County.
Caine Halter Fund
ITOR's Caine Halter Lung Cancer Research Fund initiatives will continue with the race proceeds through the established multi-year fund, which ensures lung cancer patient tissue profiling occurs at no cost to the family during their care at the Cancer Institute. Mapping of the human genome, progressive understanding of biologic cellular pathways, identification of genetic markers and proteomics, and discovered efficacy of chemotherapeutic agents have brought forth new and exciting targeted therapies. The Caine Halter Lung Cancer Research Fund will help make this and other future research projects and programs possible. As a result, ITOR in Caine’s memory will continue to drive the search for the next generation of cancer drugs using a broad and diverse array of patient tissue and treatment options.
ITOR projects have also funded projects like a Rare Tumor Immunotherapy Trial. Enrollment and treatments have begun, and the completion and publication is on target to finish by 2020. This is the only site in the United State currently conducting this trial.
2016 Funding Updates
Funds from the 9th annual Run4Life event, contributed to the Caine Halter Lung Fund as well as contributed to the upfit of the ITOR's Clincal Reserach Unit (CRU) including:
- Three new CRU exam rooms for a total of six rooms
- Two new private beds
- New uplifiting artwork and amenities for the families receiving care in the CRU
- Expanding ITOR infusion area including four new patient infusion chairs for a total of 13 chairs in the CRU
Funds from the 2016 race developed a labratory test that determines the optimal chemothreapy or targeted therapy in patients with Non-Small Cell Lung Cancer (NSCLC) with brain metastasis. This project is still in phase one and early findings indicate that phase two testing is likely.
Previous race proceeds have funded local projects like lung cancer assay validation, lung cancer personalized medicine projects, and a lung cancer stem cell target identification pilot project.